Genprex to Present Positive Biomarker Data for Reqorsa® at ASCO 2026
Event summary
- Genprex's abstract on predictive biomarkers for Reqorsa® selected for ASCO 2026 Annual Meeting (May 29–June 2, 2026).
- Data suggests biomarkers may predict patient response to Reqorsa®, potentially improving lung cancer trial outcomes.
- Reqorsa® is a systemic gene therapy targeting tumor suppressor protein TUSC2 in cancer cells.
- Genprex's lung cancer programs have received FDA Fast Track and Orphan Drug Designations.
The big picture
Genprex's ASCO presentation underscores the growing importance of biomarker-driven precision medicine in oncology. The company's non-viral gene therapy approach positions it in a competitive but expanding market for lung cancer treatments, where predictive biomarkers could enhance patient selection and trial efficiency. The strategic focus on both NSCLC and SCLC, with FDA designations in place, suggests a targeted path toward potential regulatory approvals.
What we're watching
- Clinical Validation
- Whether the biomarker data can translate into improved progression-free survival (PFS) in lung cancer trials.
- Regulatory Pathway
- The pace at which Genprex advances Reqorsa® through FDA-designated programs.
- Competitive Positioning
- How Genprex differentiates Reqorsa® in the growing gene therapy space for oncology.
Related topics